| Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton’s Jelly and bone marrow sources M Najar, G Raicevic, HI Boufker, HF Kazan, C De Bruyn, N Meuleman, ... Cellular immunology 264 (2), 171-179, 2010 | 370 | 2010 |
| Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells M Najar, G Raicevic, H Fayyad-Kazan, D Bron, M Toungouz, L Lagneaux Cytotherapy 18 (2), 160-171, 2016 | 320 | 2016 |
| Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6 M Najar, R Rouas, G Raicevic, HI Boufker, P Lewalle, N Meuleman, ... Cytotherapy 11 (5), 570-583, 2009 | 244 | 2009 |
| Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells G Raicevic, R Rouas, M Najar, P Stordeur, HI Boufker, D Bron, P Martiat, ... Human immunology 71 (3), 235-244, 2010 | 231 | 2010 |
| Translational control of cell division by Elongator F Bauer, A Matsuyama, J Candiracci, M Dieu, J Scheliga, DA Wolf, ... Cell reports 1 (5), 424-433, 2012 | 216* | 2012 |
| Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia H Fayyad-Kazan, N Bitar, M Najar, P Lewalle, M Fayyad-Kazan, R Badran, ... Journal of translational medicine 11 (1), 31, 2013 | 204 | 2013 |
| The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties G Raicevic, M Najar, B Stamatopoulos, C De Bruyn, N Meuleman, D Bron, ... Cellular immunology 270 (2), 207-216, 2011 | 188 | 2011 |
| Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming M Najar, G Raicevic, HF Kazan, C De Bruyn, D Bron, M Toungouz, ... Stem Cell Reviews and Reports 8 (4), 1188-1198, 2012 | 175 | 2012 |
| A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment C De Bruyn, M Najar, G Raicevic, N Meuleman, K Pieters, ... Stem cells and development 20 (3), 547-557, 2011 | 159 | 2011 |
| Adipose-tissue-derived and Wharton's jelly–derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor M Najar, G Raicevic, HI Boufker, H Fayyad-Kazan, C De Bruyn, ... Tissue Engineering Part A 16 (11), 3537-3546, 2010 | 153 | 2010 |
| Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue H Busser, M Najar, G Raicevic, K Pieters, R Velez Pombo, P Philippart, ... Stem cells and development 24 (18), 2142-2157, 2015 | 142 | 2015 |
| Mesenchymal stromal cells and toll-like receptor priming: a critical review M Najar, M Krayem, N Meuleman, D Bron, L Lagneaux Immune network 17 (2), 89-102, 2017 | 135 | 2017 |
| MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their … H Fayyad-Kazan, R Rouas, M Fayyad-Kazan, R Badran, N El Zein, ... Journal of Biological Chemistry 287 (13), 9910-9922, 2012 | 125 | 2012 |
| The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts H Id Boufker, L Lagneaux, M Najar, M Piccart, G Ghanem, JJ Body, ... BMC cancer 10 (1), 298, 2010 | 109 | 2010 |
| Insights into inflammatory priming of mesenchymal stromal cells: functional biological impacts M Najar, M Krayem, M Merimi, A Burny, N Meuleman, D Bron, G Raicevic, ... Inflammation Research 67 (6), 467-477, 2018 | 108 | 2018 |
| Mesenchymal stromal cell-based therapy: new perspectives and challenges M Najar, F Bouhtit, R Melki, H Afif, A Hamal, H Fahmi, M Merimi, ... Journal of clinical medicine 8 (5), 626, 2019 | 103 | 2019 |
| Characterization and functionality of the CD200–CD200R system during mesenchymal stromal cell interactions with T-lymphocytes M Najar, G Raicevic, F Jebbawi, C De Bruyn, N Meuleman, D Bron, ... Immunology Letters 146 (1-2), 50-56, 2012 | 102 | 2012 |
| The immunomodulatory potential of mesenchymal stromal cells: a story of a regulatory network M Najar, G Raicevic, E Crompot, H Fayyad-Kazan, D Bron, M Toungouz, ... Journal of immunotherapy 39 (2), 45-59, 2016 | 88 | 2016 |
| Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration M Najar, G Raicevic, H Fayyad-Kazan, C De Bruyn, D Bron, M Toungouz, ... International immunopharmacology 15 (4), 693-702, 2013 | 85 | 2013 |
| Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions M Najar, G Raicevic, HI Boufker, B Stamatopoulos, C De Bruyn, ... Experimental hematology 38 (10), 922-932, 2010 | 84 | 2010 |
